AAD 2026Abstract 74636Clinical trial
Results from an Open-Label Phase 2 Trial of ATI-2138, an investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), in patients with moderate-to-severe atopic dermatitis
Aggarwal A, Kaul A, Stillwell L, McGraw N, Maher R, Basavalingappa R, Huff E, Anderson D, Guttman E, Monahan J, Walker N
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Atopic dermatitis & eczemaSkin biology
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1536 · Not in PubMed: details from Crossref